2026-07-21T21:58:53Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/231982024-11-28T18:04:59Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16967

00925njm 22002777a 4500 dc Braso-Maristany, Fara author Sansó, Miriam author Chic, Nuria author Martinez, Debora author Gonzalez-Farre, Blanca author Sanfeliu, Esthe author Ghiglione, Lucio author Carcelero, Esther author Garcia-Corbacho, Javier author Sanchez, Marcelo author Soy, Dolors author Jares, Pedro author Peg, Vicente author Saura, Cristina author Muñoz, Montserrat author Prat, Aleix author Vivancos, Ana author 2021-09-20 The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in PD-L1-negative TNBC has been reported to date. Here, we present the case study of a woman with TNBC with low tumor infiltrating lymphocytes and PD-L1-negative disease, which achieved a significant response to atezolizumab monotherapy and durable response after the combination of atezolizumab and nab-paclitaxel. The comprehensive genomic analysis that we performed in her tumor and plasma samples revealed high tumor mutational burden (TMB), presence of the APOBEC genetic signatures, high expression of the tumor inflammation signature, and a HER2-enriched subtype by the PAM50 assay. Some of these biomarkers have been shown to independently predict response to immunotherapy in other tumors and may explain the durable response in our patient. Our work warrants further translational studies to identify biomarkers of response to immune checkpoint inhibitors in TNBC beyond PD-L1 expression and to better select patients that will benefit from immunotherapy. Braso-Maristany F, Sanso M, Chic N, Martinez D, Gonzalez-Farre B, Sanfeliu E, et al. Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer. Front Oncol. 2021 Sep 20;11:710596. 10.3389/fonc.2021.710596 2234-943X Frontiers in Oncology https://hdl.handle.net/20.500.13003/19480 34616675 L636148328 2-s2.0-85116400332 https://hdl.handle.net/20.500.12105/23198 703773100001 Immunotherapy Breast cancer Biomarkers ctDNA Case report Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer